Press-release for stocks for CMMB

Prices are updated after-hours

symbols : CMMB

save search

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
Published: 2024-04-24 (Crawled : 11:00) - globenewswire.com
CMMB | $0.67 0.02% 3.4K

Manufacturing

| 0.0% | O: 1.49% H: 0.0% C: -1.47%
first report business update therapeutics financial results

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CMMB | $0.67 0.02% 3.4K

Manufacturing

| 2.92% | O: -3.38% H: 0.0% C: 0.0%
ccl24 disease association publication sclerosis

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
Published: 2024-04-02 (Crawled : 12:00) - biospace.com/
CMMB | $0.67 0.02% 3.4K

Manufacturing

| -12.42% | O: 0.39% H: 0.26% C: -0.78%
key

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
CMMB | $0.67 0.02% 3.4K

Manufacturing

| -13.0% | O: -2.74% H: 6.8% C: -2.94%
cm-101 patent antibody

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
Published: 2024-03-07 (Crawled : 12:00) - prnewswire.com
CMMB | $0.67 0.02% 3.4K

Manufacturing

| -5.67% | O: 0.39% H: 14.99% C: 12.19%
year update therapeutics financial results

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
Published: 2024-02-20 (Crawled : 12:00) - prnewswire.com
CMMB | $0.67 0.02% 3.4K

Manufacturing

| 6.37% | O: 6.37% H: 6.3% C: 0.0%
cm-101 antibody

Chemomab Therapeutics to Participate in Upcoming Investor Conferences
Published: 2024-02-05 (Crawled : 12:00) - prnewswire.com
CMMB | $0.67 0.02% 3.4K

Manufacturing

| 17.54% | O: 0.0% H: 6.56% C: 6.56%
therapeutics

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
Published: 2024-01-30 (Crawled : 13:00) - biospace.com/
CMMB | $0.67 0.02% 3.4K

Manufacturing

| 24.07% | O: 5.56% H: 5.26% C: 1.75%
ccl24 antibody publication cm-101 therapeutics potential

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis
Published: 2023-11-15 (Crawled : 15:30) - biospace.com/
CMMB | $0.67 0.02% 3.4K

Manufacturing

| 9.84% | O: 67.21% H: 5.88% C: -19.9%
cm-101 fda treatment designation therapeutics

Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-11-09 (Crawled : 14:30) - biospace.com/
CMMB | $0.67 0.02% 3.4K

Manufacturing

| 4.85% | O: -2.97% H: 8.06% C: -3.23%
update therapeutics financial results

Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update
Published: 2023-10-30 (Crawled : 11:00) - prnewswire.com
CMMB | $0.67 0.02% 3.4K

Manufacturing

| -15.93% | O: -0.88% H: 5.05% C: -6.33%
report business update therapeutics financial results

Chemomab Therapeutics to Present at Upcoming Scientific Conferences - October 26, 2023
Published: 2023-10-26 (Crawled : 14:00) - biospace.com/
CMMB | $0.67 0.02% 3.4K

Manufacturing

| -18.29% | O: -1.22% H: 6.17% C: 1.28%
therapeutics

Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update
Published: 2023-08-14 (Crawled : 12:00) - prnewswire.com
CMMB | $0.67 0.02% 3.4K

Manufacturing

| -43.22% | O: -5.08% H: 6.24% C: 0.89%
update therapeutics financial results

Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis
Published: 2023-06-28 (Crawled : 14:00) - biospace.com/
CMMB | $0.67 0.02% 3.4K

Manufacturing

| -48.06% | O: -4.65% H: 1.03% C: -0.76%
ccl24 publication therapeutics

Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023
Published: 2023-06-26 (Crawled : 13:00) - biospace.com/
CMMB | $0.67 0.02% 3.4K

Manufacturing

| -33.0% | O: 8.0% H: 33.33% C: 18.52%
cm-101 treatment therapeutics potential

Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023
Published: 2023-06-21 (Crawled : 12:00) - biospace.com/
CMMB | $0.67 0.02% 3.4K

Manufacturing

| -61.49% | O: 0.57% H: 1.14% C: -13.71%
liver positive fibrosis trial therapeutics nash

Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update
Published: 2023-06-05 (Crawled : 12:20) - biospace.com/
CMMB | $0.67 0.02% 3.4K

Manufacturing

| -61.27% | O: 0.0% H: 1.45% C: -1.73%
update therapeutics

Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis
Published: 2023-06-02 (Crawled : 13:00) - prnewswire.com
CMMB | $0.67 0.02% 3.4K

Manufacturing

| -58.13% | O: 0.0% H: 8.74% C: 8.12%
ccl24 sclerosis

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
Published: 2023-05-24 (Crawled : 12:20) - biospace.com/
CMMB | $0.67 0.02% 3.4K

Manufacturing

| -61.71% | O: 0.0% H: 0.0% C: -3.43%
therapeutics